insiderbuyingselling Posted - 5 hours ago

$RARE new insider selling: 354 shares. http://insiderbuyingselling.com/?t=RARE

xbibackto70s Posted - 1 day ago

$RARE bios+ earnings=80% go down Fing sector sucks

epsguid Posted - 1 day ago

$RARE reported a loss of $2.03, consensus was ($1.72) via @eWhispers #epsmiss http://eps.sh/d/rare

Stock_Titan Posted - 1 day ago

$RARE Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update https://www.stocktitan.net/news/RARE/ultragenyx-reports-first-quarter-2024-financial-results-and-t5sjjtpnp1d9.html

Quantumup Posted - 04/30/24

BTIG raised the PT on $MREO to $6 was $4/Buy + raised the probability of success (PoS) for setrusumab in Ol to 90% was 75%: 📝setrusumab reduced annualized fracture rate by 67% following 6mo Tx across 24 OI pts vs SoC bisphosphonate = 20% =g setrusumab to sig improve on SoC: $RARE

Berakhot Posted - 04/30/24

$RARE $MREO

Stock_Titan Posted - 04/30/24

$RARE Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease https://www.stocktitan.net/news/RARE/ultragenyx-issues-2023-corporate-responsibility-report-showcasing-wc1ktfbvtfuw.html

OutperformGER Posted - 04/30/24

$MREO and $RARE 👇

OutperformGER Posted - 04/30/24

$MREO and $RARE 👇

briefingcom Posted - 04/30/24

$RARE: Ultragenyx Pharma announces that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies evaluating setrusumab (UX143) in pediatric and young adult patients with osteogenesis imperfecta

Elvira007 Posted - 04/30/24

$MREO $RARE already completed enrollment of its "recently" launched Orbit & cosmic Phase 3 studies and CEO is still talking about partnering Alveletstat for over 24 months. CEO needs to be removed once and for all......

Stock_Titan Posted - 04/30/24

$RARE Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) https://www.stocktitan.net/news/RARE/ultragenyx-announces-completion-of-enrollment-in-phase-3-orbit-and-po3p9jctg5yl.html

Stock_Titan Posted - 04/25/24

$RARE Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update https://www.stocktitan.net/news/RARE/ultragenyx-to-host-conference-call-for-first-quarter-2024-financial-bv0nd6bnjkhs.html

Thestocktraderhubzee Posted - 04/24/24

$RARE TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $61

Stocksrunner Posted - 04/23/24

🎉 Exciting Analyst Upgrades Today! $DDOG Datadog surges post-Wells Fargo's upgrade to Overweight. $QCOM Qualcomm gains momentum as Benchmark initiates coverage with a Buy rating. $EQR BMO Capital upgrades Equity Residential to Outperform from Market Perform. $RARE RBC Capital initiates coverage of Ultragenyx Pharmaceutical with an Outperform recommendation. $RHI Truist Securities raises outlook for Robert Half from Sell to Hold. Stay tuned for potential opportunities! https://stocksrunner.com/upgrades

DonCorleone77 Posted - 04/22/24

$RARE Ultragenyx initiated with an Outperform at RBC Capital RBC Capital analyst Luca Issi initiated coverage of Ultragenyx Pharmaceutical with an Outperform rating and $77 price target. The company has a $500M base business growing 30% ann7ally, which "protects the downside," the analyst tells investors in a research note. The firm is "impressed" by the 67% reduction in bone fractures seen for osteogenesis imperfecta and thinks it can be a $1B opportunity for Ultragenyx. The Phase III is "likely to hit," contends RBC.

erevnon Posted - 04/22/24

RBC Capital initiates coverage on Ultragenyx Pharmaceutical $RARE at Outperform rating and a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

lidopete Posted - 04/22/24

$RARE $MREO 04:50 Rec-Initiate Ultragenyx initiated with an Outperform at RBC Capital RBC Capital analyst Luca Issi initiated coverage of Ultragenyx Pharmaceutical with an Outperform rating and $77 price target. The company has a $500M base business growing 30% ann7ally, which "protects the downside," the analyst tells investors in a research note. The firm is "impressed" by the 67% reduction in bone fractures seen for osteogenesis imperfecta and thinks it can be a $1Billion opportunity for Ultragenyx. The Phase III is "likely to hit," contends RBC.

insiderbuyingselling Posted - 04/19/24

$RARE new insider selling: 142 shares. http://insiderbuyingselling.com/?t=RARE

Stock_Titan Posted - 04/19/24

$RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-mc9bf36of5qv.html

Pianomemo Posted - 04/15/24

$RARE Guess they have no real endpoints which makes it hard to measure if it is a success like survival etc

briefingcom Posted - 04/15/24

$RARE: Ultragenyx Pharma (-6.4%) announces new data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240415070441RARE&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

TraderMK Posted - 04/15/24

$RARE reports positive results but the stock tanks? What am I missing?

OpenOutcrier Posted - 04/15/24

$RARE (-7.4% pre) Ultragenyx Pharma (RARE) Reports Positive Interim Phase 1/2 Data with GTX-102 - SI https://ooc.bz/l/30338

xbibackto70s Posted - 04/15/24

$XBI recap for Monday. No buyouts, shocking! Shit data by $rare, and massive fail by $mrns down 70%+. And zero positive news today by biotech. Short this to the ground! It’s garbage!

basscat12 Posted - 04/15/24

$RARE $MOH $SNBR $CRM Pre-Market Gap Down, delayed, courtesy barchart, presented here for @Vegas1 to help us follow the money!

Maverick11 Posted - 04/15/24

$VKTX Fully fully loaded here w/ addition of May 80 calls on Friday. Added $RARE to this AM ahead of conference call - nonsensical action there. Fantastic opportunity. Continue to add $ALCC - AI name (energy) led by Sam Altman.

briefingcom Posted - 04/15/24

Gapping down: $MRNS -74.2% $NMRA -13.7% $RARE -10.4% $CRM -2.6%

OutperformGER Posted - 04/15/24

$RARE @USMA67Korea 👇

DonCorleone77 Posted - 04/15/24

$RARE Ultragenyx announces results from interim Phase 1/2 data of GTX-102 Ultragenyx Pharmaceutical announced new data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome. Expansion Cohorts at Day 170: Cognition assessed by Bayley-4 showed rapid and clinically significant improvement compared with Natural History data. Day 170 data were consistent with the treatment benefit observed in the Dose-escalation Cohorts at a similar timepoint. Behavior assessed by the Angelman Severity Assessment showed rapid improvement exceeding the treatment benefit observed in the Dose-escalation Cohorts at Day 170. Hyperactivity and noncompliance assessed by the Aberrant Behavior Checklist-Community showed rapid and clinically significant improvement at Day 170 compared with Natural History data, providing further insight into one of the most commonly reported behavioral issues. Sleep assessed by ASA showed rapid and clinically meaningful improvement exceeding treatment benefit observed in the Dose-escalation Cohorts at Day 170. Receptive communication assessed by Bayley-4 showed rapid improvement compared with Natural History data. Day 170 data were consistent with the treatment benefit observed in the Dose-escalation Cohorts at a similar timepoint. Gross Motor function assessed by ASA showed rapid improvement exceeding the treatment benefit observed in the Dose-escalation Cohorts at Day 170. Gross motor assessments as measured by Bayley-4 were not performed at Day 170 in the Expansion Cohorts to reduce patient testing burden and are not included in this analysis at this timepoint. Multi-domain Responder Index analysis across the four domains of Cognition, Receptive Communication, Behavior and Sleep resulted in a total net response of +2.0. The majority of patients had already achieved a total net response of +2 to +4 domains, demonstrating improvement exceeding the minimally important difference threshold in several domains even at this early Day 170 timepoint. Dose-escalation Cohorts up to Day 758: Cognition assessed by Bayley-4 showed continuing long-term improvement compared with Natural History data and exceeded the threshold of clinical significance by many-fold in many patients. Behavior assessed by ASA showed continuing clinically meaningful improvement. Sleep assessed by ASA showed sustained clinically meaningful improvement. Receptive communication measured by Bayley-4 showed sustained and clinically significant improvement compared with Natural History data. Gross motor function assessed by Bayley-4 showed continued and clinically significant improvement compared with previously reported Natural History data. MDRI analysis across the four domains of Cognition, Receptive Communication, Behavior and Sleep resulted in a total net response of +2.0 (p-value = 0.0007) at Day 338. The majority of patients had a total net response of +2 to +4, as well as a 2- to 5-fold improvement over the MID threshold in several domains.